Recent 8-K filings for TEVA

• April 29, 2026, 7:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Teva Q1 revenues $4.0B (+2% YoY); AUSTEDO up 41%; to acquire Emalex for $700M cash

  Q1 GAAP diluted EPS $0.31; Non-GAAP diluted EPS $0.53; revenues $3,982M (+2% USD, -3% LC).

• January 28, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Teva posts FY 2025 revenue $17.3B (+4% YoY), non-GAAP EPS $2.93, guides FY26 rev $16.4-16.8B

  FY 2025 revenues $17.3B (+4% YoY); GAAP diluted EPS $1.21, non-GAAP diluted EPS $2.93.

• January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Teva pre-announces 2025 revenue $16.8-$17.0B, raises guidance; projects 2030 mid-single-digit CAGR

  Expected 2025 revenue $16.8-$17.0B (low end), adjusted EBITDA $4.8-$5.0B (midpoint).

• December 11, 2025, 6:59 PM ET debt materiality 0.60 neutral item 1.01item 2.03item 9.01

  Teva extends revolving credit facility maturity to April 2028, adjusts leverage covenants

  Maturity extended from April 2027 to April 2028 via second one-year extension of the revolving facility.

• November 5, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Teva Q3 2025: revenue $4.48B (+3%), non-GAAP EPS $0.78; Austedo outlook raised; TAPI sale restart

  Revenue $4.48B (+3% YoY); GAAP EPS $0.37, non-GAAP EPS $0.78 (vs $0.69 YoY).

• July 30, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Teva Q2 2025 Non-GAAP EPS $0.66 (+9% YoY); Raises 2025 Innovative Product Revenue Outlook

  Revenues $4.176B flat YoY; GAAP EPS $0.24; Non-GAAP EPS $0.66 (up from $0.61).

• May 28, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03item 9.01

  Teva issues €1B and $1.2B in senior notes to refinance debt, upsizes tender offer to $2.25B

  €1B of 4.125% Senior Notes due 2031; $500M of 6.000% notes due 2032; $700M of 5.750% notes due 2030.

• May 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Teva Q1 2025: revenue $3.9B (+5% LC), Non-GAAP EPS $0.52 (+8% YoY); raises FY outlook

  Q1 revenue $3.9B (+5% local currency, +2% reported); GAAP EPS $0.18, Non-GAAP EPS $0.52 (vs $0.48 YoY).

• January 29, 2025, 6:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Teva FY2024 revenue $16.5B, GAAP EPS loss $1.45; non-GAAP EPS $2.49; sees 2025 rev $16.8-17.4B

  FY2024 revenues $16.5B, +4% USD (+6% local currency); GAAP net loss $1.639B ($1.45/share) vs $559M loss in FY2023.

• November 6, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Teva Q3 rev $4.3B (+13% YoY); raises FY2024 guidance; Austedo $435M (+28%)

  Q3 revenues $4.3B (+13% USD, +15% local currency); Non-GAAP diluted EPS $0.69 vs $0.60 YoY.

• July 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Teva Q2 revenue $4.2B +7%, non-GAAP EPS $0.61, raises full-year 2024 guidance

  Revenue $4.2B (+7% USD, +11% local currency); GAAP loss $0.75/share, non-GAAP EPS $0.61.

• June 25, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 1.01

  Teva settles Israeli tax dispute for ~$750M over 2008-2020, plus up to $500M contingent

  Teva to pay ~$750M to Israeli Tax Authorities over 2024-2029 for tax years 2008-2020.

• May 8, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Teva Q1 revenue $3.8B (+4% YoY), non-GAAP EPS $0.48, reaffirms FY24 guidance

  Revenue $3.819B (+4% YoY, +5% local currency); generics up 9% globally.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

9 positive 2 negative 8 neutral

source · TEVA on sec.gov